The Efficacy of <scp>Short‐Term</scp> Bridging Strategies With High‐ and <scp>Low‐Dose</scp> Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A <scp>Double‐Blind</scp>, Randomized, <scp>Placebo‐Controlled</scp> Trial
D. Krause, Anna Mai, Renate Klaaßen‐Mielke, Nina Timmesfeld, Ulrike Trampisch, Henrik Rudolf, Xenofon Baraliakos, E. Schmitz, C. Fendler, Claudia Klink, Stephanie Boeddeker, Ertan Saracbasi‐Zender, Hans‐Joachim Christoph, M. Igelmann, Hans‐Juergen Menne, Albert Schmid, Rolf Rau, Siegfried Wassenberg, Nilüfer Sonuc, Claudia Ose, Carmen Schade‐Brittinger, Hans J. Trampisch, Jürgen Braun
Abstract
OBJECTIVE: In active early rheumatoid arthritis (RA), glucocorticoids are often used for bridging, due to the delayed action of methotrexate. This study was undertaken to compare the effect of 3 bridging strategies, including high-dose and low-dose prednisolone, on radiographic and clinical outcomes. METHODS: Adult RA patients from 1 rheumatology hospital and 23 rheumatology practices who presented with moderate/high disease activity were randomized (1:1:1) to receive 60 mg prednisolone (high-dose prednisolone [HDP]) or 10 mg prednisolone (low-dose prednisolone [LDP]) daily (tapered to 0 mg within 12 weeks) or placebo. The 12-week intervention period was followed by 40 weeks of therapy at the physicians' discretion. The primary outcome measure was radiographic change at 1 year measured using the total modified Sharp/van der Heijde score (SHS). Disease activity was assessed with the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR). RESULTS: Of 395 randomized patients (HDP, n = 132; LDP, n = 131; placebo, n = 132), 375 (95%) remained in the modified intention-to-treat analysis. Mean ± SD changes in SHS scores in the 3 groups after 1 year were comparable: mean ± SD 1.0 ± 2.0 units in the HDP group, 1.1 ± 2.2 units in the LDP group, and 1.1 ± 1.5 units in the placebo group. The primary analysis showed no superiority of HDP compared to placebo (estimated difference of the mean change -0.04 [95% confidence interval (95% CI) -0.5, 0.4]). At week 12, the mean DAS28-ESR differed: -0.6 (95% CI -1.0, -0.2) for HDP versus placebo; -0.8 (95% CI -1.2, -0.5) for LDP versus placebo. At week 52, there was no significant difference in DAS28-ESR between the 3 groups (range 2.6-2.8). Serious adverse events occurred similarly often. CONCLUSION: Short-term glucocorticoid bridging therapy at a high dose showed no benefit with regard to progression of radiographic damage at 1 year.